Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection

Transplantation

Volumn 82, Issue 12, 2006, Pages 1649-1652

  Thai, Ngoc L ^a,d   Blisard, Deanna ^a   Tom, Kusum ^a   Basu, Amit ^a   Smetanka, Cindy ^a   Tan, Henkie ^a   Bentlejewski, Carol ^a   Glidewell, Janice ^a   Britz, Judy ^b   Kowalski, Richard ^b   Shapiro, Ron ^a   Fung, John ^c   Marcos, Amadeo ^a   Zeevi, Adriana ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Cylex Incorporated   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Campath 1H; Immune monitoring; Pancreas transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALEMTUZUMAB; CIDOFOVIR; COTRIMOXAZOLE; GANCICLOVIR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; TACROLIMUS; VALGANCICLOVIR;

ANEMIA; BLOOD SAMPLING; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYPTOCOCCAL MENINGITIS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC KIT; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MONOTHERAPY; PANCREAS TRANSPLANTATION; PARVOVIRUS INFECTION; PRIORITY JOURNAL; SEPSIS; STATISTICAL SIGNIFICANCE; SUPERINFECTION; T LYMPHOCYTE; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND INFECTION;

ADENOSINE TRIPHOSPHATE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BIOLOGICAL ASSAY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MONITORING, IMMUNOLOGIC; PANCREAS TRANSPLANTATION; T-LYMPHOCYTES; TACROLIMUS;

EID: 33845929149     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000250655.14026.5c     Document Type: Conference Paper

References (8)

1. Thai NL, Abu-Almagd K, Khan A, et al. Pancreatic Transplantation at the University of Pittsburgh. Clin Transplants 2004; 205.
2. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation; 2006; 82: 1621.
3. Thai NL, Khan A, Basu A, et al. Campath-1H induction in pancreas transplantation: FK monotherapy and FK/MMF. Boston, MA: World Transplant Congress, 2006.
4. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17(2): 77.
5. Isaacs JD, Greer S, Sharma S, et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 2001; 44(9): 1998.
6. Zeevi A, Britz JA, Bentlejewski CA, et al. Monitoring Immune Function during Tacrolimus Tapering in Small Bowel Transplant Recipients. Transplant Immunology 2005; 15(1): 17.
7. Cadillo-Chavez R, de Echegaray S, Santiago-Delpin EA, et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc 2006; 38(3): 918.
8. Kowalski R, Post D, Mannon R, et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006; 1-27.